TITLE

Antibacterial effect of Manuka honey on Clostridium difficile

AUTHOR(S)
Hammond, Eric N.; Donkor, Eric S.
PUB. DATE
June 2013
SOURCE
BMC Research Notes;2013, Vol. 6 Issue 1, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Manuka honey originates from the manuka tree (Leptospermum scoparium) and its antimicrobial effect has been attributed to a property referred to as Unique Manuka Factor that is absent in other types of honey. Antibacterial activity of Manuka honey has been documented for several bacterial pathogens, however there is no information on Clostridium difficile, an important nosocomial pathogen. In this study we investigated susceptibility of C. difficile to Manuka honey and whether the activity is bactericidal or bacteriostatic. Methods: Three C. difficile strains were subjected to the broth dilution method to determine minimum inhibitory concentrations (MIC) and minimum bactericidal concentrations (MBC) for Manuka honey. The agar well diffusion method was also used to investigate sensitivity of the C. difficile strains to Manuka honey. Results: The MIC values of the three C. difficile strains were the same (6.25% v/v). Similarly, MBC values of the three C. difficile strains were the same (6.25% v/v). The activity of Manuka honey against all three C. difficile strains was bactericidal. A dose-response relationship was observed between the concentrations of Manuka honey and zones of inhibition formed by the C. difficile strains, in which increasing concentrations of Manuka honey resulted in increasing size of zone of inhibition formed. Maximum zone of inhibition was observed at 50% (v/v) Manuka honey and the growth inhibition persisted over 7 days. Conclusion: C. difficile is appreciably susceptible to Manuka honey and this may offer an effective way of treating infections caused by the organism.
ACCESSION #
88014087

 

Related Articles

  • Clostridium difficile exposure as an insidious source of infection in healthcare settings: an epidemiological model. Yakob, Laith; Riley, Thomas V.; Paterson, David L.; Clements, Archie C. A. // BMC Infectious Diseases;2013, Vol. 13 Issue 1, p1 

    Background: Clostridium difficile is the leading cause of infectious diarrhea in hospitalized patients. Its epidemiology has shifted in recent years from almost exclusively infecting elderly patients in whom the gut microbiota has been disturbed by antimicrobials, to now also infecting...

  • Antimicrobial Activities of Fidaxomicin. Goldstein, Ellie J. C.; Babakhani, Farah; Citron, Diane M. // Clinical Infectious Diseases;Aug2012 Supplement 2, Vol. 55 Issue suppl_2, pS143 

    Fidaxomicin is bactericidal against Clostridium difficile. The combined results of 8 in vitro studies of 1323 C. difficile isolates showed the minimum inhibitory concentration (MIC) range of fidaxomicin to be ≤0.001–1 μg/mL, with a maximum MIC for inhibition of 90% of organisms...

  • Derivation and validation of a simple clinical bedside score (ATLAS) for Clostridium difficile infection which predicts response to therapy. Miller, Mark A.; Louie, Thomas; Mullane, Kathleen; Weiss, Karl; Lentnek, Arnold; Golan, Yoav; Kean, Yin; Sears, Pam // BMC Infectious Diseases;2013, Vol. 13 Issue 1, p1 

    Background: Clostridium difficile infection (CDI) continues to be a frequent and potentially severe infection. There is currently no validated clinical tool for use at the time of CDI diagnosis to categorize patients in order to predict response to therapy. Methods: Six clinical and laboratory...

  • Multidrug resistance in European Clostridium difficile clinical isolates. Spigaglia, Patrizia; Barbanti, Fabrizio; Mastrantonio, Paola // Journal of Antimicrobial Chemotherapy (JAC);Oct2011, Vol. 66 Issue 10, p2227 

    Objectives Multidrug resistance and antibiotic resistance mechanisms were investigated in 316 Clostridium difficile clinical isolates collected during the first European surveillance on C. difficile in 2005. Methods MICs of eight different antibiotics were determined using Etest. Reserpine- and...

  • Tolevamer, a Novel Nonantibiotic Polymer, Compared with Vancomycin in the Treatment of Mild to Moderately Severe Clostridium difficile-Associated Diarrhea. Louie, Thomas J.; Peppe, Jennifer; Watt, C. Kevin; Johnson, David; Mohammed, Rasheed; Dow, Gordon; Weiss, Karl; Simon, Stuart; John, Jr., Joseph F.; Garber, Gary; Chasan-Taber, Scott; Davidson, David M. // Clinical Infectious Diseases;8/15/2006, Vol. 43 Issue 4, p411 

    Background. Current antibiotic therapies for Clostridium difficile-associated diarrhea have limitations, including progression to severe disease, recurrent C. difficile-associated diarrhea, and selection for nosocomial pathogens. Tolevamer, a soluble, high-molecular weight, anionic polymer that...

  • OPTIMIZING THE USE OF Carbapenems IN THE FACE OF INCREASING GRAM-NEGATIVE RESISTANCE.  // Formulary;Jul2007 Supplement, Vol. 42, p3 

    The article focuses on the clinical and economic impact of carbapenems, an antibiotic with a broad spectrum of antibacterial activity, in the U.S. The drug possesses a broad spectrum of activity that threatens the superinfections by fungi and resistant bacteria including the collateral damage in...

  • Antimicrobial-Associated Risk Factors for Clostridium difficile Infection. Owens Jr., Robert C.; Donskey, Curtis J.; Gaynes, Robert P.; Loo, Vivian G.; Muto, Carlene A. // Clinical Infectious Diseases;1/15/2008 Supplement 1, Vol. 46 Issue 1, pS19 

    Antimicrobial therapy plays a central role in the pathogenesis of Clostridium difficile infection (CDI), presumably through disruption of indigenous intestinal microflora, thereby allowing C. difficile to grow and produce toxin. Investigations involving animal models and studies performed in...

  • Evaluation of the effect of oritavancin on Clostridium difficile spore germination, outgrowth and recovery. Chilton, C. H.; Freeman, J.; Baines, S. D.; Crowther, G. S.; Nicholson, S.; Wilcox, M. H. // Journal of Antimicrobial Chemotherapy (JAC);Sep2013, Vol. 68 Issue 9, p2078 

    Objectives Previous work suggests oritavancin may be inhibitory to Clostridium difficile spores. We have evaluated the effects of oritavancin exposure on C. difficile spore germination, outgrowth and recovery. Methods Germination and outgrowth of C. difficile spores exposed to different...

  • Vancomycin for the Treatment of Clostridium difficile Infection: For Whom Is This Expensive Bullet Really Magic? Pepin, Jacques // Clinical Infectious Diseases;5/15/2008, Vol. 46 Issue 10, p1493 

    The epidemiology, clinical severity, and case-fatality ratio of Clostridium difficile infection (CDI) changed dramatically with the emergence of a toxin hyperproducing strain (BI/NAP1/027) in North America and Europe in 2000. For the treatment of CDI, metronidazole and vancomycin remain the 2...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics